ERC Starting Grant · 2017
Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are difficult to develop (e.g., crossing the peculiar cell wall of Mycobacterium tuberculosis), promising un(der)explored targets and unconventional hit-identification strategies are needed. I have selected three anti-infective targets based on their biochemical context for which few or no small-molecule inhibitors are known: 1) The antimalarial and antituberculotic drug target DXS is part of a unique biosynthetic pathway for pathogens that is absent in humans, thereby…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.